Loading...



Shopping cart processing ...
0
Your cart0
Products 0
Price $0.00
Bestsellers Pill categories
Customer Support 24/7
usa canada USA
uk UK
au AU
Live Chat 24/7
Menu
Customer Support 24/7
USA/Canada Toll Free USA
UK UK
AUS AU
Customer Support 24/7
usacanada USA
uk UK
au AU
We accept
  • Visa
  • MasterCard
  • Amex
  • JCB
Currency
USD
Your cart: $0.00 (0 items)
Checkout

Categories list

Choosing us you get:

  • Reliable supplier
  • Low Internet prices
  • Free bonus pills
  • Discount on all future orders
  • Discreet package
  • SSL secure orders
Worldwide Shipping!

Testimonials:

  • Leo Ahlstrom Werribee, Australia
    I can hardly believe that I spent so much money on brand drugs. Your generic drugs act the same way the brand ones do but they cost much more cheaper. Thank you. Now I know about your site and will buy again and again.
More info »

Zovirax

Zovirax
Zovirax is a drug applied to treat chickenpox (varicella) or shingles (herpes zoster) and treat or restrain genital herpes infections. The drug may also be prescribed by your doctor for other ailments.

Brand: Acyclovir

Availability: In Stock
Average Delivery Time: 9 Days
Exp. Date: June 2024
Package Price Per pill Save Order
Zovirax 800 mg
270 pills - 800 mg
+ 12 free Viagra 100 mg, 7% discount for future orders
$485.99 $1.80 $305.56 Add to cart
180 pills - 800 mg
+ 12 free Viagra 100 mg, 7% discount for future orders
$335.99 $1.87 $191.71 Add to cart
120 pills - 800 mg
+ 8 free Viagra 100 mg, 5% discount for future orders
$237.99 $1.98 $113.81 Add to cart
90 pills - 800 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$185.99 $2.07 $77.86 Add to cart
60 pills - 800 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$137.99 $2.30 $37.91 Add to cart
30 pills - 800 mg $87.95 $2.93 No Add to cart
Zovirax 400 mg
360 pills - 400 mg
+ 8 free Viagra 100 mg, 5% discount for future orders
$242.99 $0.67 $180.97 Add to cart
270 pills - 400 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$191.99 $0.71 $125.98 Add to cart
180 pills - 400 mg
+ 4 free Viagra 100 mg, 3% discount for future orders
$135.99 $0.76 $75.99 Add to cart
120 pills - 400 mg $99.93 $0.83 $41.39 Add to cart
90 pills - 400 mg $79.99 $0.89 $26.00 Add to cart
60 pills - 400 mg $59.95 $1.00 $10.71 Add to cart
30 pills - 400 mg $35.33 $1.18 No Add to cart
Zovirax 200 mg
180 pills - 200 mg $52.99 $0.29 $36.86 Add to cart
120 pills - 200 mg $41.99 $0.35 $17.91 Add to cart
90 pills - 200 mg $34.99 $0.39 $9.94 Add to cart
60 pills - 200 mg $29.95 $0.50 No Add to cart

Product description

Drug title

Zovirax (Acyclovir)

Pharmacological action

Antiviral drug, synthetic analog of purine nucleoside, which has the ability to inhibit in vitro and in vivo replication of Herpes simplex virus types 1 and 2, Varicella zoster virus, Epstein-Barr virus (EBV) and cytomegalovirus (CMV). In cell culture, acyclovir has the most pronounced antiviral activity against Herpes simplex type 1, followed in descending order of activity by Herpes simplex type 2, Varicella zoster, EBV and CMV.


The effect of acyclovir on viruses is highly selective. Acyclovir is not a substrate for thymidine kinase enzyme of uninfected cells, so it is little toxic to mammalian cells. Thymidine kinase of cells infected with Herpes simplex virus types 1 and 2, Varicella zoster, EBV and CMV converts acyclovir to acyclovir monophosphate, a nucleoside analog, which is then sequentially converted to diphosphate and triphosphate by cellular enzymes. Incorporation of acyclovir triphosphate into the chain of viral DNA and subsequent breaking of the chain blocks further replication of viral DNA.


In patients with severe immunodeficiency, prolonged or repeated courses of acyclovir therapy can lead to the formation of resistant strains, and therefore further treatment with acyclovir may not be effective. Most acyclovir-resistant strains isolated have relatively low levels of viral thymidine kinase, impaired viral thymidine kinase structure or DNA polymerase. Exposure of Herpes simplex virus strains to acyclovir in vitro can also lead to the formation of less sensitive strains. No correlation has been established between the sensitivity of Herpes simplex virus strains to acyclovir in vitro and the clinical efficacy of the drug.


Pharmacokinetics

Absorption


When administered orally, acyclovir is only partially absorbed from the intestine. When 200 mg of acyclovir was taken every 4 hours, the mean CSSmax in plasma was 3.1 µmol (0.7 µg/mL) and the mean CSSmin was 1.8 µmol (0.4 µg/mL). When 400 mg and 800 mg of acyclovir were given every 4 hours, CSSmax was 5.3 μmol (1.2 μg/mL) and 8 μmol (1.8 μg/mL), respectively, and mean CSSmin was 2.7 μmol (0.6 μg/mL) and 4 μmol (0.9 μg/mL), respectively.


Distribution


The concentration of acyclovir in cerebrospinal fluid is approximately 50% of its plasma concentration. Acyclovir binds only slightly (9-33%) to plasma proteins.


Metabolism and excretion


The main metabolite of acyclovir is 9-carboxymethoxy-methylguanine, which contributes about 10-15% of the administered dose of the drug in the urine.


T1/2 is 2.5-3.3 h. Most of the drug is excreted unchanged by the kidneys. Renal clearance of acyclovir significantly exceeds creatinine clearance, which indicates excretion of acyclovir not only by glomerular filtration, but also by tubular secretion. When administering acyclovir in 1 hour after taking 1 g probenecid T1/2 and AUC increased by 18 and 40% respectively.


Pharmacokinetics in special clinical cases


In patients with chronic renal failure, the T1/2 of acyclovir averaged 19.5 hours; with hemodialysis, it averaged 5.7 hours; and the plasma concentration of acyclovir decreased by approximately 60%.


In elderly people, acyclovir clearance decreases with age in parallel with a decrease in creatinine clearance, but the T1/2 of acyclovir changes insignificantly.


When acyclovir and zidovudine were administered simultaneously to HIV-infected patients, the pharmacokinetic characteristics of both drugs remained virtually unchanged.

Contraindications for use

  • Hypersensitivity to acyclovir or valacyclovir.

Caution is used in case of dehydration and renal failure.

Administration during pregnancy and lactation

Administration of Zovirax during pregnancy and lactation (breastfeeding) requires caution and is possible only after an assessment of the estimated benefit to the mother and the potential risk to the fetus and child.


No increase in birth defects has been found in children whose mothers received Zovirax during pregnancy compared to the general population.


After oral administration of Zovirax at a dose of 200 mg 5 times daily, acyclovir was detected in breast milk at concentrations ranging from 0.6-4.1% of plasma concentrations. At these concentrations in breast milk, breastfed children can receive acyclovir at doses up to 300 micrograms/kg/day.


Administration in renal impairment

In patients with renal insufficiency, oral administration of acyclovir in recommended doses for treatment and prevention of infections caused by Herpes simplex viruses does not lead to cumulation of the drug to concentrations exceeding the established safe levels. However, in patients with a CKR of less than 10 ml/min, the dose of Zovirax should be reduced to 200 mg 2 times/day (every 12 hours). For treatment of varicella, herpes zoster and also for treatment of patients with severe immunodeficiency at IQ less than 10 ml/min, the recommended dose of Zovirax is 800 mg 2 times/day every 12 hours; at IQ 10-25 ml/min, 800 mg 3 times/day every 8 hours.

Administration in children

Treatment and prevention of infections caused by Herpes simplex viruses in immunodeficient children 2 years of age and older - the same doses as for adults; under 2 years of age - half the adult dose.


For treatment of chickenpox in children over 6 years old, the drug is prescribed in a single dose of 800 mg; 2 to 6 years old, 400 mg; under 2 years old, 200 mg. The frequency of administration is 4 times per day. A more precise single dose can be determined at the rate of 20 mg/kg body weight (but no more than 800 mg). The course of treatment is 5 days.


There are no data on the use of Zovirax for the prevention of recurrent infections caused by Herpes simplex viruses and for the treatment of herpes zoster in children with normal immunity parameters.


The very limited data available indicate that doses of Zovirax for the treatment of children over 2 years of age with severe immunodeficiency are similar to those for adults.


Use in elderly patients

Elderly patients should receive adequate fluids while taking Zovirax orally in high doses.

Indications of Zovirax

  • Treatment of skin and mucous membrane infections caused by Herpes simplex virus types 1 and 2, including primary and recurrent genital herpes;
  • Prevention of recurrence of infections caused by Herpes simplex virus types 1 and 2 in patients with normal immune status;
  • prevention of infections caused by Herpes simplex virus type 1 and 2 in immunodeficient patients;
  • treatment of infections caused by Varicella zoster virus (chicken pox and herpes zoster);
  • treatment of patients with severe immunodeficiency, mainly with HIV infection (CD4+ cell count <200/μL), with early clinical manifestations of HIV infection and with the unfolding clinical picture of AIDS), who have undergone bone marrow transplantation.

Dosing regimen

For the treatment of infections caused by Herpes simplex virus types 1 and 2 in adults, the recommended dose of Zovirax is 200 mg 5 times daily every 4 hours (except for bedtime). The course of treatment is usually 5 days, but may be prolonged in severe primary infections.


In severe immunodeficiency (e.g., after bone marrow transplantation) or in intestinal absorption disorders, the oral dose of Zovirax may be increased to 400 mg 5 times/day. Treatment should be started as soon as possible after the onset of infection; in relapses, the drug should be administered as early as in the prodromal period or when the first rash elements appear.


For prophylaxis of recurrences of infections caused by Herpes simplex virus types 1 and 2 in patients with normal immune status, the recommended dose of Zovirax is 200 mg 4 times per day (every 6 hours). A more convenient scheme of therapy is suitable for many patients: 400 mg 2 times per day (every 12 hours). In some cases, lower doses of Zovirax are effective: 200 mg 3 times/day (every 8 hours) or 2 times/day (every 12 hours). Treatment with Zovirax should be periodically interrupted for 6-12 months in order to determine any changes in the course of the disease.


For prophylaxis of infections caused by Herpes simplex virus types 1 and 2 in immunodeficient patients, the recommended dose of Zovirax is 200 mg 4 times/day (every 6 hours). In patients with severe immunodeficiency (e.g. after a bone marrow transplant) or with impaired intestinal absorption, the oral dose of Zovirax can be increased to 400 mg 5 times daily. The duration of prophylactic therapy is determined by the duration of the period of risk of infection.


For treatment of chicken pox and herpes zoster, the recommended dose of Zovirax is 800 mg 5 times/day, taken every 4 hours, except for bedtime. The course of treatment is 7 days.


The drug should be prescribed as soon as possible after the onset of infection, because in this case the treatment is more effective.


For the treatment of patients with severe immunodeficiency, the recommended dose of Zovirax is 800 mg 4 times/day (every 6 hours).


For patients who have undergone bone marrow transplantation, a course of 1 month of IV therapy with acyclovir is usually recommended before oral administration of Zovirax. During clinical trials, the maximum duration of treatment of bone marrow transplant recipients was 6 months (from the 1st month to the 7th month after transplantation). In patients with advanced clinical manifestation of HIV infection the duration of treatment with Zovirax was 12 months, but there is reason to believe that longer courses of therapy can be effective in these patients.


Treatment and prevention of infections caused by Herpes simplex viruses in children with immunodeficiency at the age of 2 years and older - the same doses as for adults; at the age under 2 years - half the dose for adults.


For treatment of chickenpox in children over 6 years old, the drug is prescribed in a single dose of 800 mg; 2 to 6 years old, 400 mg; under 2 years old, 200 mg. The frequency of administration is 4 times per day. A more precise single dose can be determined at the rate of 20 mg/kg body weight (but not more than 800 mg). The course of treatment is 5 days.


There are no data on the use of Zovirax for the prevention of recurrent infections caused by Herpes simplex viruses and for the treatment of herpes zoster in children with normal immunity parameters.


According to the very limited data available, the same doses of Zovirax for treatment of children over 2 years of age with severe immunodeficiency can be used as for treatment of adults.


When prescribing Zovirax to elderly patients, the possibility of a decrease in acyclovir clearance together with a decrease in creatinine clearance should be taken into account. In the presence of signs of renal failure, it is necessary to consider reducing the dose of Zovirax. Elderly patients should receive sufficient fluids while taking Zovirax orally in high doses.


In patients with renal insufficiency, oral administration of acyclovir in recommended doses for treatment and prevention of infections caused by Herpes simplex viruses does not lead to cumulation of the drug to concentrations exceeding the established safe levels. However, in patients with a CKR of less than 10 ml/min, the dose of Zovirax should be reduced to 200 mg 2 times/day (every 12 hours). For treatment of varicella, herpes zoster, and patients with severe immunodeficiency with a KC less than 10 mL/min, recommended doses of Zovirax are 800 mg 2 times/day every 12 h; for KC 10-25 mL/min, 800 mg 3 times/day every 8 h.


Zovirax tablets can be taken with food because eating does not significantly interfere with its absorption. The tablets should be washed down with a full glass of water.